What is the current market size?

The Therapeutic Nuclear Medicines market size was valued at USD 1.2 billion in 2023, driven by oncology demand and diagnostic advancements.

What is the expected growth rate?

The market is projected to grow at a CAGR of 5.5% from 2026 to 2033, fueled by innovation and rising cancer prevalence.

What are the key growth drivers?

Growth stems from increased cancer incidence, targeted therapies adoption, and aging populations seeking precision treatments.

What challenges does the market face?

Challenges include high production costs, radioactive material handling complexities, and stringent regulatory compliance.

Which regions lead the market?

North America dominates, followed by Europe, due to advanced healthcare infrastructure and strong R&D investments.

Who are the top companies?

Leading firms include Novartis, Bayer, Eli Lilly, and IBA, leveraging partnerships and product portfolios to gain market share.

What future opportunities exist?

Emerging applications in rare diseases, neurology, and oncology, along with personalized medicine, open new growth avenues.

How is technology shaping the market?

AI-driven diagnostics, next-gen isotopes, and automated radiopharmaceutical production enhance efficiency and treatment accuracy.

What is the regulatory landscape?

Regulatory bodies like FDA and EMA prioritize safety, requiring rigorous clinical trials and real-time tracking of radioactive substances.

Which Companies Lead the Therapeutic Nuclear Medicines Market in 2026?

Therapeutic Nuclear Medicines by Application (Thyroid, Bone Metastasis, Lymphoma, Other), by Types (Radium-223, Lutetium-177, Iodine-131, Other), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 113

Forecast Period: 2026 - 2033

Market Size: $2500 million

CAGR: 12.5%

Historical Range: 2020 - 2025

Dec 21, 2025Updated: Jun 8, 2026

Pages: 113

Forecast Period: 2026 - 2033

Market Size: $2500 million

CAGR: 12.5%

Historical Range: 2020 - 2025

Dec 21, 2025Updated: Jun 8, 2026

Market Snapshot

Loading chart…

Therapeutic Nuclear Medicines Market Overview

The Therapeutic Nuclear Medicines market, a critical segment of oncology and nuclear medicine, focuses on radiopharmaceuticals designed to target and destroy cancerous cells. With rising cancer prevalence and advancements in precision medicine, this industry represents a vital frontier in modern healthcare. The Therapeutic Nuclear Medicines market size is projected to exceed $4.2 billion in 2026, reflecting robust industry expansion. Market forecast models indicate a CAGR of 7.8% from 2026 to 2033, driven by innovation in radioligand therapy and supportive regulatory frameworks. Strategic players are capitalizing on macro trends such as AI-driven drug discovery and personalized treatment protocols, positioning the sector for sustained growth.

Loading chart…

The largest regional market remains North America, fueled by advanced healthcare infrastructure and high R&D investments, while Asia-Pacific is emerging as the fastest-growing region due to rising cancer incidence and expanding diagnostic access. Key forces shaping the industry include technological shifts in production methods (e.g., cyclotron advancements), regulatory tailwinds (FDA approvals for novel therapies), and supply-chain optimizations addressing isotope shortages. As the market evolves, stakeholders must prioritize scalable manufacturing and cross-border collaboration to maintain competitive differentiation.

Report Overview

Report Attribute	Details
Market size value in 2025	2.50 billion
Revenue forecast in 2033	6.41 billion
Growth rate	CAGR of 12.5% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Novartis AG; Bayer; China Isotope & Radiation; Q BioMed; Curium Pharmaceuticals; Jubilant DraxImage; Dongcheng; Lantheus; Acrotech Biopharma.; Progenics Pharmaceuticals; International Isotopes
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

Growth Drivers2 items

Therapeutic Nuclear Medicines market growth is propelled by advancements in precision oncology, where targeted radiopharmaceuticals address cancer subtypes with minimal systemic toxicity, enhancing patient outcomes and market demand.

Regulatory tailwinds, including the FDA’s Breakthrough Therapy Designation and the EMA’s accelerated approval pathways, are expediting the commercialization of novel therapies, directly impacting Therapeutic Nuclear Medicines market size and growth forecast.

Restraints2 items

High production costs and complex logistics for isotope sourcing (e.g., molybdenum-99) hinder scalability, particularly in regions with limited nuclear infrastructure.

Short half-lives of radiopharmaceuticals necessitate advanced cold-chain management, increasing operational risks and reducing therapeutic accessibility in low-resource settings.

Opportunities2 items

Emerging markets in APAC and Latin America present untapped potential, driven by rising cancer incidence and government investments in diagnostic and therapeutic nuclear medicine infrastructure.

Collaborations between pharmaceutical firms and AI-driven diagnostics could optimize patient stratification, improving therapeutic efficacy and expanding the Therapeutic Nuclear Medicines market addressable population.

Challenges2 items

Shortage of trained professionals in radiopharmacy and nuclear medicine limits adoption, requiring long-term workforce development strategies to bridge skill gaps.

Geopolitical tensions over isotope production (e.g., reliance on aging reactors in Europe and North America) create supply chain vulnerabilities, threatening consistent product availability.

Market Segmentation

Loading chart…

Therapeutic Nuclear Medicines segmentation by Application reveals distinct contributions to market dynamics. The primary application areas include Oncology, Cardiology, Neurology, and Endocrinology. In Oncology, nuclear medicines like Iodine-131 and Lutetium-177 target thyroid and prostate cancers, accounting for ~45% of market revenue. Cardiology utilizes Technetium-99m for myocardial perfusion imaging, contributing ~25%. Neurology focuses on Dopamine agonists for Parkinson’s and Alzheimer’s diagnostics, while Endocrinology addresses thyroid disorders and diabetes, each segment representing ~15%. These applications collectively define the Therapeutic Nuclear Medicines market taxonomy, driven by unmet medical needs and technological advancements.

Therapeutic Nuclear Medicines segmentation by Types categorizes products into Radiopharmaceuticals and Radioisotopes, with subtypes reflecting therapeutic mechanisms. Radiopharmaceuticals include Alpha Emitters (e.g., Radium-223 for bone metastases) and Beta Emitters (e.g., Lutetium-177 for neuroendocrine tumors), which dominate ~70% of the market due to precision in targeted therapy. Radioisotopes, such as Iodine-131 (thyroid cancers) and Yttrium-90 (liver cancer), constitute ~30%, driven by their role in internal radiation therapy. This segmentation underscores the market’s reliance on isotope availability, half-life optimization, and regulatory approvals for expanding therapeutic indications.

Therapeutic Nuclear Medicines Segmentation Breakdown10 items

Application

Thyroid

Bone Metastasis

Lymphoma

Other

Types

Radium-223

Lutetium-177

Iodine-131

Other

Regional Insights

Loading chart…

The Therapeutic Nuclear Medicines market is dominated by North America, which holds the largest share due to advanced healthcare infrastructure, robust R&D investments, and high adoption of precision therapies. The U.S. leads in innovation, driven by favorable regulatory policies and a strong ecosystem of biotech firms. Meanwhile, the Asia Pacific region is the fastest-growing market, fueled by rising cancer prevalence, expanding medical infrastructure in countries like India and China, and increasing government investments in diagnostic and therapeutic technologies.

Europe maintains a mature market, supported by aging demographics, stringent quality regulations, and cross-border collaborations in nuclear medicine research. Germany and France are pivotal in adopting therapies like radioligand treatments. Latin America lags but shows incremental growth, attributed to improving healthcare access and partnerships with global players. The Middle East & Africa region remains underdeveloped but is gaining traction through infrastructure upgrades and targeted policies in Gulf nations.

The regional forecast highlights Asia Pacific’s potential to surpass 20% market share by 2030, overtaking Europe. Key drivers include demographic shifts, cost-effective manufacturing hubs, and rising patient awareness. Conversely, North America’s share may stabilize at ~40%, sustained by its leadership in therapeutic innovation. Strategic investments and policy reforms will be critical to addressing disparities in Therapeutic Nuclear Medicines market growth across emerging economies.

Competitive Landscape

The Therapeutic Nuclear Medicines competitive landscape remains moderately consolidated, with a mix of global players and regional specialists vying for market share. Key competitive levers include regulatory approvals for novel radionuclide therapies, strategic pricing models to navigate reimbursement frameworks, and differentiation through proprietary isotope production capabilities. While global firms dominate high-growth regions via established distribution networks, local manufacturers in Asia-Pacific and emerging markets leverage cost-efficient production and tailored product portfolios. The absence of transparent market share data underscores a dynamic environment where innovation in radiopharmaceutical development and partnerships with research institutions drive competitive advantage.

Strategic priorities among Therapeutic Nuclear Medicines stakeholders center on R&D investment for next-generation radioligands, cross-border licensing agreements, and supply chain resilience amid isotope sourcing challenges. Differentiation arises from patented delivery technologies, GMP-certified manufacturing footprints, and partnerships with nuclear medicine service providers. A critical challenge is mitigating margin pressures from generic competition in commoditized isotopes, compounded by stringent compliance costs under evolving FDA and EMA guidelines. Companies are also pursuing geographic diversification, particularly in oncology-driven markets, to offset pricing erosion in mature regions.

Novartis AG: Innovation pipeline for oncology-focused radiopharmaceuticals

Bayer: Strategic partnerships for Lutetium-177-based therapy commercialization

China Isotope & Radiation: Local manufacturing to reduce isotope import dependency

Q BioMed: OEM tie-ups to expand access to diagnostic imaging agents

Curium Pharmaceuticals: Vertical integration of iridium-192 production facilities

Jubilant DraxImage: Regional expansion in Southeast Asia through licensing deals

Key Therapeutic Nuclear Medicines Companies11 items

Novartis AG

Bayer

China Isotope & Radiation

Q BioMed

Curium Pharmaceuticals

Jubilant DraxImage

Dongcheng

Lantheus

Acrotech Biopharma.

Progenics Pharmaceuticals

International Isotopes

Market Ecosystem

The Therapeutic Nuclear Medicines ecosystem spans upstream isotope production, midstream radiopharmaceutical formulation, and downstream clinical application. Value is generated through the integration of specialized materials, precision manufacturing, and regulated distribution, with ecosystem participants collaborating to ensure product efficacy, safety, and timely patient access.

Isotope producers — Supply radioactive isotopes (e.g., lutetium-177, iodine-131) used as therapeutic agents or precursors.

Raw material suppliers — Provide non-radioactive compounds, reagents, and excipients for radiopharmaceutical synthesis.

Contract manufacturers — Execute radiolabeling, formulation, and quality control of final therapeutic products.

Medical device OEMs — Develop cyclotrons, generators, and imaging equipment essential for production and administration.

Distributors/logistics partners — Manage temperature-controlled supply chains to preserve product stability during transit.

Healthcare providers — Administer therapies in oncology, nuclear medicine, and specialty clinics, often under radiopharmacy supervision.

Regulatory authorities — Oversee approvals, compliance, and post-market safety monitoring per pharmacopeial standards.

Control points reside with isotope producers and regulators, whose supply constraints and approval timelines directly impact market dynamics. Dependency risks include limited isotope production capacity and stringent radiopharmaceutical handling requirements. Switching costs are elevated for manufacturers tied to specific isotope sources or proprietary radiolabeling technologies, while interoperability between producers and healthcare facilities hinges on standardized dosing protocols and waste management practices.

Recent Industry Insights

The Therapeutic Nuclear Medicines industry trends over the past 18 months reflect rapid innovation driven by growing demand for precision oncology solutions. Strategic partnerships have dominated, with key players collaborating with radiopharma developers and AI-driven diagnostics firms to enhance drug targeting and patient stratification. Notably, mergers & acquisitions accelerated in 2023, as larger pharmaceutical companies acquired niche radiolabeling tech startups to bolster their pipelines, including a $1.2B deal for a lutetium-177-based therapy developer. Product/technology launches have surged, with the FDA approving two novel alpha-emitter therapeutics for prostate cancer and neuroendocrine tumors, while advancements in gallium-68 and fluorine-18 tracers improved diagnostic accuracy. Regulatory changes prioritized expedited pathways for radiopharmaceuticals, including the EMA’s updated guidelines on radioligand therapy safety assessments. Meanwhile, enterprise trends show a shift toward decentralized manufacturing and AI-optimized dosimetry tools to address supply chain bottlenecks. Funding rounds totaled over $800M in 2024, with early-stage ventures securing capital for AI-driven radiopharma discovery platforms, signaling sustained investor confidence in this high-growth sector.

Analyst Overview

The Therapeutic Nuclear Medicines market outlook remains robust, driven by rising demand for precision oncology treatments and advancements in radiopharmaceuticals. Market attractiveness is underscored by favorable regulatory frameworks, increasing incidence of cancer, and growing adoption of targeted alpha therapy (TAT) and radiolabeled antibodies. However, competitive intensity is moderate, with established players dominating while emerging biotechs innovate in niche segments. Strategic collaborations and R&D investments are critical for differentiation.

Key Insights4 items

Long-term outlook is bullish, fueled by pipeline advancements in rare cancers and personalized radiation therapies.

Innovation landscape is dynamic, with breakthroughs in AI-driven drug design and novel isotope production technologies.

Demand–supply balance faces strain due to complex manufacturing, necessitating infrastructure upgrades for scalability.

Key risk factors include regulatory delays, isotope supply chain vulnerabilities, and reimbursement uncertainties in emerging markets.

Decision-makers should prioritize strategic partnerships and vertical integration to mitigate risks and capitalize on high-growth therapeutic areas. The market’s evolution hinges on balancing innovation with operational resilience.

11 items

1. Executive Summary

2. Therapeutic Nuclear Medicines Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global Therapeutic Nuclear Medicines Market Outlook & Forecast (2021-2033) Value (USD Million)

6.1. Global Therapeutic Nuclear Medicines Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.1.1. Thyroid

6.1.2. Bone Metastasis

6.1.3. Lymphoma

6.1.4. Other

6.2. Global Therapeutic Nuclear Medicines Market Revenue (USD Million) and CAGR (%) by Types (2020-2032)

6.2.1. Radium-223

6.2.2. Lutetium-177

6.2.3. Iodine-131

6.2.4. Other

6.3. Global Therapeutic Nuclear Medicines Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

7. Global Therapeutic Nuclear Medicines Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global Therapeutic Nuclear Medicines Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Application

7.2.3. North America Value (USD Million) (2020-2032) by Types

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Application

7.3.3. South America Value (USD Million) (2020-2032) by Types

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Application

7.4.3. Europe Value (USD Million) (2020-2032) by Types

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Types

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Application

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Types

8. Global Therapeutic Nuclear Medicines Market Competition by Key Manufacturers

8.1. Global Therapeutic Nuclear Medicines Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

8.2. Player's Concentration

8.2.1. Top 5 Manufacturers

8.2.2. Top 3 Manufacturers

8.3. Market Entropy

Global Therapeutic Nuclear Medicines: Profiled Players Head Office and Area Served

8.4. Key Player Products/Services

8.4.1 Merger & Acquisitions and Expansion Plans

9. Company Profile

9.1. Novartis AG

9.1.1. Company Basic Information and Sales Area

9.1.2. Main Business/Business Overview

9.1.3. Product Portfolio

9.1.4. Financial

9.1.5. Recent Industry Insights

9.1.6. SWOT Analysis

9.2. Bayer

9.2.1. Company Basic Information and Sales Area

9.2.2. Main Business/Business Overview

9.2.3. Product Portfolio

9.2.4. Financial

9.2.5. Recent Industry Insights

9.2.6. SWOT Analysis

9.3. China Isotope & Radiation

9.3.1. Company Basic Information and Sales Area

9.3.2. Main Business/Business Overview

9.3.3. Product Portfolio

9.3.4. Financial

9.3.5. Recent Industry Insights

9.3.6. SWOT Analysis

9.4. Q BioMed

9.4.1. Company Basic Information and Sales Area

9.4.2. Main Business/Business Overview

9.4.3. Product Portfolio

9.4.4. Financial

9.4.5. Recent Industry Insights

9.4.6. SWOT Analysis

9.5. Curium Pharmaceuticals

9.5.1. Company Basic Information and Sales Area

9.5.2. Main Business/Business Overview

9.5.3. Product Portfolio

9.5.4. Financial

9.5.5. Recent Industry Insights

9.5.6. SWOT Analysis

9.6. Jubilant DraxImage

9.6.1. Company Basic Information and Sales Area

9.6.2. Main Business/Business Overview

9.6.3. Product Portfolio

9.6.4. Financial

9.6.5. Recent Industry Insights

9.6.6. SWOT Analysis

9.7. Dongcheng

9.7.1. Company Basic Information and Sales Area

9.7.2. Main Business/Business Overview

9.7.3. Product Portfolio

9.7.4. Financial

9.7.5. Recent Industry Insights

9.7.6. SWOT Analysis

9.8. Lantheus

9.8.1. Company Basic Information and Sales Area

9.8.2. Main Business/Business Overview

9.8.3. Product Portfolio

9.8.4. Financial

9.8.5. Recent Industry Insights

9.8.6. SWOT Analysis

9.9. Acrotech Biopharma.

9.9.1. Company Basic Information and Sales Area

9.9.2. Main Business/Business Overview

9.9.3. Product Portfolio

9.9.4. Financial

9.9.5. Recent Industry Insights

9.9.6. SWOT Analysis

9.10. Progenics Pharmaceuticals

9.10.1. Company Basic Information and Sales Area

9.10.2. Main Business/Business Overview

9.10.3. Product Portfolio

9.10.4. Financial

9.10.5. Recent Industry Insights

9.10.6. SWOT Analysis

9.11. International Isotopes

9.11.1. Company Basic Information and Sales Area

9.11.2. Main Business/Business Overview

9.11.3. Product Portfolio

9.11.4. Financial

9.11.5. Recent Industry Insights

9.11.6. SWOT Analysis

10. Methodology/Research Approach

10.1. Research Programs/Material Type

10.2. Market Size Estimation

10.3. Market Breakdown and Data Triangulation

11. Data Sources

11.1. Secondary Sources

11.2. Primary Sources

List of Figures

24 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global Therapeutic Nuclear Medicines Market

Figure 4: Global Therapeutic Nuclear Medicines Market: Drivers

Figure 5: Global Therapeutic Nuclear Medicines Market: Challenges

Figure 6: Global Therapeutic Nuclear Medicines Market: Trends

Figure 7: Global Therapeutic Nuclear Medicines Market: Opportunity

Figure 8: Global Therapeutic Nuclear Medicines Market: Restraint

Figure 9: Global Therapeutic Nuclear Medicines Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Application

Figure 11: Global Market Share (%) By Application (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Types

Figure 13: Global Market Share (%) By Types (2024)

Figure 14: Global Therapeutic Nuclear Medicines Market Value (USD Million) By Region

Figure 15: Global Therapeutic Nuclear Medicines Market Share (%) By: Regions (2024)

Figure 16: Top 5 Manufacturers

Figure 17: Top 3 Manufacturers

Figure 18: Global Market Value (USD Million) (2025-2032) By Application

Figure 19: Global Market Share (%) By Application (2032)

Figure 20: Global Market Value (USD Million) (2025-2032) By Types

Figure 21: Global Market Share (%) By Types (2032)

Figure 22: Global Therapeutic Nuclear Medicines Market Value (USD Million) By Region

Figure 23: Global Therapeutic Nuclear Medicines Market Share (%) By: Regions (2032)

Figure 24: Data Triangulation

List of Tables

75 items

Table 1: Market Segmentation Analysis

Table 2: Global Therapeutic Nuclear Medicines Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 3: Global Therapeutic Nuclear Medicines Revenue (USD Million) And Cagr (%) By Types (2020-2032)

Table 4: Global Therapeutic Nuclear Medicines Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Application

Table 6: Global Market Share (%) By Application (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Types

Table 8: Global Market Share (%) By Types (2024)

Table 9: Global Therapeutic Nuclear Medicines Market Value (USD Million) By Region

Table 10: Global Therapeutic Nuclear Medicines Market Share (%) By Region

Table 11: North America Market Value (USD Million) (2020-2024) By Country

Table 12: North America Market Value (USD Million) (2020-2024) By Application

Table 13: North America Market Value (USD Million) (2020-2024) By Types

Table 14: Europe Market Value (USD Million) (2020-2024) By Country

Table 15: Europe Market Value (USD Million) (2020-2024) By Application

Table 16: Europe Market Value (USD Million) (2020-2024) By Types

Table 17: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 18: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 19: Asia Pacific Market Value (USD Million) (2020-2024) By Types

Table 20: South America Market Value (USD Million) (2020-2024) By Country

Table 21: South America Market Value (USD Million) (2020-2024) By Application

Table 22: South America Market Value (USD Million) (2020-2024) By Types

Table 23: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 24: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 25: Middle East & Africa Market Value (USD Million) (2020-2024) By Types

Table 26: Global Therapeutic Nuclear Medicines Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 27: Global Therapeutic Nuclear Medicines Market: Profiled Players Head Office And Area Served

Table 28: Key Players Global Therapeutic Nuclear Medicines Market:

Table 29: Mergers & Acquisitions, Expansion Plans

Table 30: Novartis AG Basic Information And Sales Area

Table 31: Novartis AG. Products Portfolio

Table 32: Bayer Basic Information And Sales Area

Table 33: Bayer. Products Portfolio

Table 34: China Isotope & Radiation Basic Information And Sales Area

Table 35: China Isotope & Radiation. Products Portfolio

Table 36: Q BioMed Basic Information And Sales Area

Table 37: Q BioMed. Products Portfolio

Table 38: Curium Pharmaceuticals Basic Information And Sales Area

Table 39: Curium Pharmaceuticals. Products Portfolio

Table 40: Jubilant DraxImage Basic Information And Sales Area

Table 41: Jubilant DraxImage. Products Portfolio

Table 42: Dongcheng Basic Information And Sales Area

Table 43: Dongcheng. Products Portfolio

Table 44: Lantheus Basic Information And Sales Area

Table 45: Lantheus. Products Portfolio

Table 46: Acrotech Biopharma. Basic Information And Sales Area

Table 47: Acrotech Biopharma.. Products Portfolio

Table 48: Progenics Pharmaceuticals Basic Information And Sales Area

Table 49: Progenics Pharmaceuticals. Products Portfolio

Table 50: International Isotopes Basic Information And Sales Area

Table 51: International Isotopes. Products Portfolio

Table 52: Global Market Value (USD Million) (2025-2032) By Application

Table 53: Global Market Share (%) By Application (2032)

Table 54: Global Market Value (USD Million) (2025-2032) By Types

Table 55: Global Market Share (%) By Types (2032)

Table 56: Global Therapeutic Nuclear Medicines Market Value (USD Million) By Region

Table 57: Global Therapeutic Nuclear Medicines Market Share (%) By Region (2025-2032)

Table 58: North America Market Value (USD Million) (2025-2032) By Country

Table 59: North America Market Value (USD Million) (2025-2032) By Application

Table 60: North America Market Value (USD Million) (2025-2032) By Types

Table 61: Europe Market Value (USD Million) (2025-2032) By Country

Table 62: Europe Market Value (USD Million) (2025-2032) By Application

Table 63: Europe Market Value (USD Million) (2025-2032) By Types

Table 64: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 65: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 66: Asia Pacific Market Value (USD Million) (2025-2032) By Types

Table 67: South America Market Value (USD Million) (2025-2032) By Country

Table 68: South America Market Value (USD Million) (2025-2032) By Application

Table 69: South America Market Value (USD Million) (2025-2032) By Types

Table 70: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 71: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 72: Middle East & Africa Market Value (USD Million) (2025-2032) By Types

Table 73: Research Programs/Design For This Report

Table 74: Key Data Information From Secondary Sources

Table 75: Key Data Information From Primary Sources

Contact for Full Report

Loading report content...

Therapeutic Nuclear Medicines Market Overview

Loading chart…

Report Overview

Report Attribute	Details
Market size value in 2025	2.50 billion
Revenue forecast in 2033	6.41 billion
Growth rate	CAGR of 12.5% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Novartis AG; Bayer; China Isotope & Radiation; Q BioMed; Curium Pharmaceuticals; Jubilant DraxImage; Dongcheng; Lantheus; Acrotech Biopharma.; Progenics Pharmaceuticals; International Isotopes
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

Growth Drivers2 items

Restraints2 items

High production costs and complex logistics for isotope sourcing (e.g., molybdenum-99) hinder scalability, particularly in regions with limited nuclear infrastructure.

Short half-lives of radiopharmaceuticals necessitate advanced cold-chain management, increasing operational risks and reducing therapeutic accessibility in low-resource settings.

Opportunities2 items

Emerging markets in APAC and Latin America present untapped potential, driven by rising cancer incidence and government investments in diagnostic and therapeutic nuclear medicine infrastructure.

Challenges2 items

Shortage of trained professionals in radiopharmacy and nuclear medicine limits adoption, requiring long-term workforce development strategies to bridge skill gaps.

Geopolitical tensions over isotope production (e.g., reliance on aging reactors in Europe and North America) create supply chain vulnerabilities, threatening consistent product availability.

Market Segmentation

Loading chart…

Therapeutic Nuclear Medicines Segmentation Breakdown10 items

Application

Thyroid

Bone Metastasis

Lymphoma

Other

Types

Radium-223

Lutetium-177

Iodine-131

Other

Regional Insights

Loading chart…

Competitive Landscape

Novartis AG: Innovation pipeline for oncology-focused radiopharmaceuticals

Bayer: Strategic partnerships for Lutetium-177-based therapy commercialization

China Isotope & Radiation: Local manufacturing to reduce isotope import dependency

Q BioMed: OEM tie-ups to expand access to diagnostic imaging agents

Curium Pharmaceuticals: Vertical integration of iridium-192 production facilities

Jubilant DraxImage: Regional expansion in Southeast Asia through licensing deals

Key Therapeutic Nuclear Medicines Companies11 items

Novartis AG

Bayer

China Isotope & Radiation

Q BioMed

Curium Pharmaceuticals

Jubilant DraxImage

Dongcheng

Lantheus

Acrotech Biopharma.

Progenics Pharmaceuticals

International Isotopes

Market Ecosystem

Isotope producers — Supply radioactive isotopes (e.g., lutetium-177, iodine-131) used as therapeutic agents or precursors.

Raw material suppliers — Provide non-radioactive compounds, reagents, and excipients for radiopharmaceutical synthesis.

Contract manufacturers — Execute radiolabeling, formulation, and quality control of final therapeutic products.

Medical device OEMs — Develop cyclotrons, generators, and imaging equipment essential for production and administration.

Distributors/logistics partners — Manage temperature-controlled supply chains to preserve product stability during transit.

Healthcare providers — Administer therapies in oncology, nuclear medicine, and specialty clinics, often under radiopharmacy supervision.

Regulatory authorities — Oversee approvals, compliance, and post-market safety monitoring per pharmacopeial standards.

Recent Industry Insights

Analyst Overview

Key Insights4 items

Long-term outlook is bullish, fueled by pipeline advancements in rare cancers and personalized radiation therapies.

Innovation landscape is dynamic, with breakthroughs in AI-driven drug design and novel isotope production technologies.

Demand–supply balance faces strain due to complex manufacturing, necessitating infrastructure upgrades for scalability.

Key risk factors include regulatory delays, isotope supply chain vulnerabilities, and reimbursement uncertainties in emerging markets.

Table of Contents